The U.S. Food and Drug Administration (FDA) has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs, U.S. media reported Tuesday.
Ixempra, distributed by Bristol-Meyers Squibb Company, was approved for use in combination with another cancer drug, capecitabine, in patients who no longer benefit from two other chemotherapy treatments. These prior treatments included an anthracycline and a taxane.
It was also approved for use alone in patients who no longer benefit from an anthracycline, a taxane and capecitabine.
According to the American Cancer Society, about 180,000 new cases of breast cancer are diagnosed each year in the United States. Metastatic breast cancer is the most advanced stage of breast cancer and has the potential to spread to almost any region of the body.
Ixempra has been shown to bind to cancer cell microtubules, which are structures within cells that help to support and shape them. Microtubules also play a role in cell division. Ixempra is administered by intravenous injection.
Source:Xinhua
|
Comment
Tell A Friend
Print Format
Save Article